

February 17, 2021

The Honorable Richard Hilderbrand, Chairperson
Senate Committee on Public Health and Welfare
Statehouse, Room 445A-S
Topeka, Kansas 66612

Dear Senator Hilderbrand:


SUBJECT: Fiscal Note for SB 200 by Senate Committee on Public Health and Welfare

In accordance with KSA 75-3715a, the following fiscal note concerning SB 200 is respectfully submitted to your committee.

SB 200 would authorize a pharmacist to test or screen for and initiate therapy for a patient in compliance with statewide protocols adopted by the Board of Pharmacy for influenza, strep, COVID-19, prophylaxis, or another waived test for clinical laboratory improvement amendments. The bill would require the Board to establish all statewide protocols and place enforcement authority under the Board.

In SB 200, the Board of Pharmacy would be responsible for developing the statewide protocol and drafting, publishing, and adopting any administrative regulations. Although, the Board indicates that enactment of the bill would likely increase staff time necessary to carry out the requirements, the requirements could be completed by the Board's current staff and are within the Board's current expertise due to the prevalence of similar statewide protocols used in other states. Any fiscal effect associated with SB 200 is not reflected in *The FY 2022 Governor's Budget Report*.

Sincerely,



Adam Proffitt
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy